TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06629467

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for smoking cessation
Description: Treatment components will include psychoeducation on the consequences of tobacco use and the benefits of quitting; therapeutic commitment; self-monitoring of cigarette smoking; brief advice on healthy eating behaviors and sleep hygiene, physiological feedback (based on CO levels), training in self-control strategies, stimulus control, management of craving with alternative activities, diaphragmatic breathing, weekly personalized physical activity objectives, and relapse prevention strategies. The protocol consists of a nicotine fading procedure, which consists of a weekly reduction in nicotine intake of 30% (based on both tobacco brands and the number of cigarettes) from the first to the fifth session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy for smoking cessation
Description: Treatment components will include psychoeducation on the consequences of tobacco use and the benefits of quitting; therapeutic commitment; self-monitoring of cigarette smoking; brief advice on healthy eating behaviors and sleep hygiene, physiological feedback (based on CO levels), training in self-control strategies, stimulus control, management of craving with alternative activities, diaphragmatic breathing, weekly personalized physical activity objectives, and relapse prevention strategies. The protocol consists of a nicotine fading procedure, which consists of a weekly reduction in nicotine intake of 30% (based on both tobacco brands and the number of cigarettes) from the first to the fifth session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized PA plan
Description: The treatment provider will fix an objective (e.g. go for brisk walking for 30 minutes 3 times this week) for each participant every week according to his/her current PA level, time availability, likes, and fitness level.
Study: NCT05549219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLM101
Description: GLM101 IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLM101
Description: GLM101 IV Infusion
Study: NCT06629467

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized PA plan
Description: The treatment provider will fix an objective (e.g. go for brisk walking for 30 minutes 3 times this week) for each participant every week according to his/her current PA level, time availability, likes, and fitness level.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit Versa 3
Description: Wearable activity tracker with the functionalities of a watch function, including time, date, calendar, and weather (connection to the internet is required). Physical activity monitoring (steps per day, active minutes per day, plants climbed, heart rate monitoring, time, intensity, caloric expenditure, and exercise type of exercise session), sleep monitoring (sleep time, sleep phases time, sleep quality), stress levels managing and guided breathing application are the main health-related functionalities.
Study: NCT04923412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary branch of vagus nerve not preserved
Description: During the mediastinal lymph node dissection using minimally invasive surgery, efforts to preserve the pulmonary branch of vagus nerve is not made/ can be severed.
Study: NCT05549219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLM101
Description: GLM101 IV Infusion
Study: NCT06246422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 500 MG
Description: Local instillation of 500 mg tranexamic acid in 20 ml normal saline in the gall bladder bed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Local instillation of 20 ml normal saline in the gall bladder bed
Study: NCT06491095

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 0 g Flax
Description: 175 g yogurt with no flax product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g whole ground flaxseed
Description: 175 g yogurt with 40 g whole ground flaxseed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g roasted then ground whole flaxseed
Description: 175 g yogurt with 40 g roasted then ground whole flaxseed

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 g of whole intact flaxseeds
Description: 175 g yogurt with 40 g of whole intact flaxseeds

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 28 g flax hulls
Description: 175 g yogurt with 28 g flax hulls
Study: NCT05459779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric wheelchair with activated assistance module
Description: This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 with activated assistance.

Intervention type: DEVICE
Group type: OTHER
Intervention: Electric wheelchair with assistance module not activated
Description: This evaluation will be carried out in 1 standardized test circuit composed by 9 platforms of increasing difficulty. The same day, the patient will perform the circuit 4 times, including 2 without activating assistance.
Study: NCT05752552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DO-2
Description: Deuterated MET kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DO-2
Description: Deuterated MET kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DO-2
Description: Deuterated MET kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DO-2
Description: Deuterated MET kinase inhibitor
Study: NCT05789381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: This drug is commonly used on labor and delivery and in the postpartum period and is easily ordered through the electronic medical record and provided. This drug requires no specific storage for research study purposes as the drug is already being administered per standard of care and national and international guidelines. The only change is in the duration of therapy. This is NOT considered an off label use of the drug and does not require any form of exemption determination. Magnesium for severe preeclampsia is often given for anywhere from 12 to 24 hours postpartum depending on the clinical scenario, provider preference, and patient symptoms/adverse reactions to the medication.
Study: NCT06247423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active group 10kHz
Description: For electrical stimulation in the active groups, unmodulated alternating currents with a symmetrical rectangular waveform of 10 kHz will be applied for 20 minutes. The current intensity shall be adjusted individually for each participant by increasing the current intensity until the participant reports a strong but comfortable tingling sensation just below the motor threshold. One electrode will be placed over the median and radial nerves, while the other over the radial nerve.~The intensity of the current shall be adjusted every two minutes if the tingling sensation decreases. This protocol had been used in previous studies conducted by our research group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Sham electrical stimulation will be performed with the same equipment, time, and electrodes as in the active groups without the participants and the evaluator having a view of the device screen. The intensity of the current will be increased for 30 seconds until the sensory threshold (strong but comfortable tingling sensation) will be reached and after that, the intensity will be reduced to 0 milliamperes (mA) with 30 seconds ramp down. Participants will not receive electrical current during the rest of the placebo intervention. This protocol was used in other studies with similar interventions to blind participants.
Study: NCT06525597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stapokibart Injection
Description: IL-4Rα monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04866407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentha x piperita
Description: 2% solution of Mentha x piperita diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Mentha x piperita' group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eucalyptus globulus
Description: 2% solution of Eucalyptus globulus diluted in fractionated coconut oil for topical application will be applied to one extremity of the subjects in the 'Eucalyptus globulus' group.
Study: NCT05331495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative Hemoperfusion
Description: During the operation, the hemoperfusion device and the membrane oxygenator of the extracorporeal circulation device were operated in parallel.
Study: NCT05140850

Intervention type: BIOLOGICAL
Intervention: neuroimaging examination,neuro-cognitive test,blood pressure,blood sample
Description: neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested

Intervention type: BIOLOGICAL
Intervention: neuroimaging examination,neuro-cognitive test,blood pressure,blood sample
Description: neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested
Study: NCT05044130

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-fat mixed-meal tolerance test (HF-MMTT)
Description: The test meal consists of a standardized HF-MMTT (791 cal) with 197 g cream (38 % fat), 18 g sugar and 1 g vanilla sugar for taste (75 g fat, 25 g carbohydrate and 4 g protein)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-fat mixed-meal tolerance test (HF-MMTT)
Description: The test meal consists of a standardized HF-MMTT (791 cal) with 197 g cream (38 % fat), 18 g sugar and 1 g vanilla sugar for taste (75 g fat, 25 g carbohydrate and 4 g protein)
Study: NCT04835584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRT-232
Description: KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
Study: NCT05549024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM26-RGD
Description: Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM26-RGD
Description: Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM26-RGD
Description: Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: 18F-FDG injection
Study: NCT05774457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice training
Description: Traditional vs. virtual reality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice training
Description: Traditional vs. virtual reality
Study: NCT06300970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amodiaquine-artesunate (ASAQ)
Description: Oral medication given for treatment of uncomplicated plasmodium falciparum infection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether+Lumefantrine (AL)
Description: Oral medication given for treatment of uncomplicated plasmodium falciparum infection.
Study: NCT06658496

Intervention type: DEVICE
Intervention: Near Infrared Spectroscopy
Description: Application of regional NIRS sensors to brain and kidney sites in the first 72 hours after birth to monitor regional tissue oxygenation.
Study: NCT05840770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT06593912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Functional Training
Description: Early functional training after 3 weeks using Air Stirrup compared to cast (standard protocol) after peroneal tendon surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol
Description: Cast 6 weeks after peroneal tendon surgery (standard protocol)
Study: NCT05050929

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Targeting All Brain Metastases
Description: Volumetric Modulated Arc Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Targeting All Brain Metastases
Description: Volumetric Modulated Arc Therapy
Study: NCT04543201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early START visit using checklist over telephone or zoom
Description: Prior to visit subject receives pre-visit educational guide and copy of advance directive form~Follow up surveys:~Immediate: provider feedback survey~2-4 weeks after visit: subject feedback survey and caregiver/family feedback survey~After subject death: caregiver/family survey
Study: NCT05961878

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: mediterranean diet with adequate protein intake
Description: balanced mediterranean diet with 1.1 g/kg die protein intake

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mediterranean diet with adequate protein intake
Description: balanced mediterranean diet with 1.1 g/kg die protein intake
Study: NCT04789681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06143800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reactivation
Description: During the retrieval phase, cues are presented to participants to reactivate their memories; participants in the non-retrieval group go directly to cognitive reappraisal phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reactivation
Description: During the retrieval phase, cues are presented to participants to reactivate their memories; participants in the non-retrieval group go directly to cognitive reappraisal phase.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive reappraisal intervention
Description: Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive reappraisal intervention
Description: Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive reappraisal intervention
Description: Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive reappraisal intervention
Description: Subsequently, in the self-focused cognitive reappraisal group, participants will be instructed to use disengagement reappraisal to separate themselves from the picture situation and draw a subjective distance so as not to strongly feel the negative emotions brought by the picture. In the context-focused reappraisal group, participants will focus on the picture situation, reappraise the meaning of the picture situation, and assign positive meanings to it.
Study: NCT05857917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual reality in PD catheter insertion surgery in the pre- and intraoperative setting.
Study: NCT05184803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel injection, oxaliplatin, S-1
Description: As a prior chemotherapy, intravenous administration is performed every 3 weeks for docetaxel 50 mg/m2 D1, intravenous administration for oxaliplatin 100 mg/m2 D1, and oral administration twice a day for S-140 mg/m2 D1 to 14.
Study: NCT05549024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM26
Description: Intravenous injection of 68Ga-RM26-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RGD
Description: Intravenous injection of 68Ga-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/ kg.
Study: NCT05607771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Vitrification
Description: Oocytes will be prepared for vitrification using the manual protocol
Study: NCT06562218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: isokinetic strengthening exercise
Description: Participants' isokinetic strength measurements will be assessed using the Cybex II Humac Norm isokinetic dynamometer. A strengthening programme will be performed for a total of 12 sessions, 3 days a week for 4 weeks, at 20 degrees of flexion, 20 degrees of extension, 60-90 and 180 degrees/s speed.~At the beginning and end of the 12th session, isokinetic and isometric muscle performance tests will be performed on the healthy wrist, and isometric wrist flexor and extensor strength measurements will be performed in neutral position 1 week after removal of the cast on the fractured wrist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional exercise programm
Description: The immobilised limb was given finger grip exercises.
Study: NCT05207787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10365
Description: Single or multiple dose(s) of HS-10365 daily or twice every day. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and/or unequivocal disease progression.
Study: NCT05607771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Vitrification
Description: Oocytes will be prepared for vitrification using the DaVitri device
Study: NCT05814640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Commonly used oral antipsychotics intervention therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Commonly used oral antipsychotics intervention therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Commonly used oral antipsychotics intervention therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Commonly used oral antipsychotics intervention therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Commonly used oral antipsychotics intervention therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Commonly used oral antipsychotics intervention therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Commonly used oral antipsychotics intervention therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GCBT
Description: Commonly used intervention therapy of psychotherapy.
Study: NCT05009485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Current Health platform
Description: A remote patient monitoring system which includes a small footprint device and tablet, combined with an AI-powered, cloud-based system driving advanced real-time and predictive analytics related to a patient's clinical condition. The wearable records heart rate, respiratory rate, oxygen saturation, skin temperature and step count.